Axitinib, also known as AG013736, is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. A xitinib has received FDA (27 January 2012), EMA (13 September 2012), MHRA (3 September 2012) and TGA (26 July 2012) approval for use as a treatment for renal cell carcinoma.
Related Products:
Pexidartinib hcl; Pexidartinib; Telatinib; Avapritinib; Amuvatinib; Dovitinib Lactate; Linifanib; OSI-930; Crenolanib; Motesanib Diphosphate; Motesanib; Sunitinib; Imatinib mesylate; Masitinib; Dovitinib; ISCK03